Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Contacts:

Dr Jurgen Raths, President and CEO,

Tel.: +41-61-417-96-60;

Harry Welten, MBA, CFO and Senior Vice President,

Tel.: +41-61-417-96-65;

Paul Verbraeken, Head of Corporate Communications,

Tel.: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... SEOUL, South Korea , Aug. 28, 2015 /PRNewswire/ ... Chungbuk National University and Dr. Ra from Biostar ... , Confirmed 30% increase of lifespan through multiple ... cognitive function, physical vitality, and life expectancy found ... Researchers in Korea have determined the possibility that adult ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Inc. (Nasdaq: CRTX ) today announced that it ... Thursday, November 4, 2010, to discuss its financial results for ... results are expected to be released on Thursday, November 4, ... in the live conference call, please dial 866-804-6927 (U.S. callers) ...
... See video from AstraZeneca at: ... Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue ... at constant exchange rates (CER) to $7,898 ... for Crestor, Symbicort and Seroquel XR. Revenue ...
Cached Medicine Technology:Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call 3
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ProDrop Particles ... . Each preset contains 15 seconds of unique footage that users can shrink and ... fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, and ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... New Port Richey, FL (PRWEB) , ... August 28, 2015 , ... ... that while many potential workers are qualified for the position they are applying for, ... work. Because of this, many employers are considering altering drug testing policies in order ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... Texas Health Care Association Urges Clinton, Obama, McCain, ... AUSTIN, Texas, Feb. 12 As Democratic,presidential ... today to compete in the increasingly important March ... urged the major,presidential candidates of both parties to ...
... FORT BELVOIR, Va., Feb. 12 Ehmke,Manufacturing ... recipients when,the Defense Logistics Agency honored 23 ... its Business Alliance Awards., Ehmke received ... Award in,the historically underutilized business (HUB) zone, ...
... Feb. 12 XTENT, Inc.,(Nasdaq: XTNT ) announced ... market close on Tuesday, February 19, 2008. The company ... p.m., Pacific Time (5 p.m. Eastern Time).,The call will ... Chief,Executive Officer, and Tim Kahlenberg, Chief Financial Officer., ...
... Spotlights Sector,s Leadership in Improving,Transparency, Expanding Public Disclosure, ... a,statement by Alan G. Rosenbloom, President of the ... for Medicare and Medicaid Services,(CMS) release today of ... in,need of improvement:, "Nursing home providers have ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that ... Mid-Cap Growth Conference on Friday, February 15,2008 at approximately ... is scheduled to be webcast live and may be ... . The webcast will,be available for 30 days following ...
... may cause women with ductal carcinoma in situ (DCIS), ... overestimate their risk of recurrence or dying from breast ... Cancer Institute in Boston. , "Although DCIS typically is ... inaccurate risk perceptions," said Ann Partridge, MD, MPH, the ...
Cached Medicine News:Health News:Growing Importance of March 4 Texas Primary Requires 2008 Presidential Candidates to Better Address Eldercare Financing Issues 2Health News:Defense Logistics Agency Recognizes Ehmke Manufacturing Company 2Health News:Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference 2Health News:Anxiety linked to newly diagnosed DCIS patients' overestimation of breast cancer risks 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Wide 1 mm x 3 mm smooth platform. Serrated handle with polished finish. Most popular size or model....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
Fine 2 mm wide platform. Cross action serrated handle with metal tip guard. Polished finish....
Medicine Products: